An interventional study of blood sample and bronchoalveolar lavage in ARDS and SARS-CoV 2 Pneumonia, sponsored by Assistance Publique Hopitaux De Marseille. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.
Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Other
Patients on mechanical ventilation (MV) following SARS-CoV-2 pneumonia frequently develop ventilator-associated pneumonia (VAP). The incidence of MVAP during SARS-CoV-2 infections ranges from 50 to nearly 90%. In addition, up to 80% of recurrences of VAP (a new episode, most often attributable to the same bacteria) have been described, reflecting the failure of the initial antibiotic therapy. This incidence is much higher than that described for other etiologies of acute respiratory distress syndrome (ARDS). The investigators hypothesize that during VAP, there is an alteration of the diffusion of intravenous antibiotics in the lung parenchyma in COVID-19 patients in relation to several factors characteristic of SARS-CoV-2 infection. This altered diffusion may explain the high number of recurrences of MVAP compared to non-COVID-19 patients.
Assistance Publique Hopitaux De Marseille is the lead sponsor of 686 studies on the registry; 148 are open to participants now.
Counted across the registry records on this site, refreshed daily.
1. Patient over 18 years of age 2. Patient has given consent or consent obtained from the trusted person if the patient is not capable of consenting, after informed consent.
3. Patient with ARDS 4. Patient requiring MV for ARDS (as defined by Berlin (15)), regardless of etiology (COVID-19 or other cause of ARDS) 5. Patient with suspected 1st episode of ARDS for which microbiological sampling is performed (bronchial aspiration, protected distal sampling (PDS), bronchoalveolar lavage (BAL)) 6. Patients who have received probabilistic antibiotic therapy within 24 hours of the microbiological sample, including piperacillin-tazobactam (PIP-TAZ) administered according to current recommendations.
7. Patient who is a beneficiary of or affiliated to a social security system
Exclusion Criteria:
Patients admitted to the ICU and placed on VM following SARS-CoV-2 pneumonia
Other: blood sample and bronchoalveolar lavage
Patients admitted to the ICU and placed on VM outside of SARS-CoV-2 pneumonia
Other: blood sample and bronchoalveolar lavage
These patients are put on VM as part of their care and present a suspicion of a 1st episode of PAVM for which a microbiological sample is taken and a probabilistic antibiotic therapy is started with the PIP-TAZ association (D0). A plasma PIP-TAZ assay will be performed 48 hours after the start of antibiotic therapy with PIP-TAZ. Blood urea will be measured and a mini-LBA (performed with a Combicatheter®) will be performed to measure PIP-TAZ and urea in the ELF. On day 7 of the antibiotic therapy (last day of the planned antibiotic therapy), the same samples are taken and the same analyses are performed + bacteriology on the mini BAL. For patients for whom antibiotic therapy has been interrupted because of sterile samples, the samples taken at D7 will not be taken. The clinical outcome of the patient will then be recorded until D60.
Compare the pulmonary diffusion of piperacillin
Dosage in the epithelial lining fluid
Time frame: 48 hours following antibiotics administration
Pulmonary diffusion of tazobactam
Dosage in the epithelial lining fluid
Time frame: 48 hours following antibiotics administration
Concentrations of piperacillin in effective pulmonary and plasma targets
Piperacillin concentrations in Epithelial Lining Fluid
Time frame: 48 hours following antibiotics administration
Concentrations of piperacillin in effective pulmonary and plasma targets
Piperacillin concentrations in plasma
Time frame: 7 days following antibiotics administration
Concentrations of tazobactam in effective pulmonary and plasma targets
Tazobactam concentrations in Epithelial Lining Fluid
Time frame: 7 days following antibiotics administration
Concentrations of tazobactam in effective pulmonary and plasma targets
Tazobactam concentrations in Epitehlial Lining Fluid and plasma separately at H48 and 7 days after initiation of antibiotic therapy
Time frame: 48 hours following antibiotics administration
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille